In vivo interferon system assessed by 2′‐5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin
- 30 October 2008
- journal article
- Published by Wiley in Hepatology Research
- Vol. 38 (12), 1213-1220
- https://doi.org/10.1111/j.1872-034x.2008.00397.x
Abstract
2',5' oligoadenylate synthetase (2-5AS), an enzyme induced by interferon, is an accurate indicator of the antiviral effect of interferon. We measured it during pegylated interferon based therapies in patients with chronic hepatitis C virus (HCV) in order to determine the dynamics of antiviral status in vivo and the relationship between the response to exogenous interferon and the outcome of therapy. A total of 160 patients with chronic HCV were treated with pegylated interferon alfa 2a or 2b or non-pegylated interferon, with or without ribavirin. Serum 2-5AS activity was measured by radioimmunoassay assay kits every 2 weeks. In 60 patients treated with pegylated interferon alfa 2a or 2b, 2-5AS levels increased to 7-40 times (average 235 pmol/dL) above the pretreatment levels (30 pmol/dL), which were significantly higher than the levels during non-pegylated interferon therapy. Ribavirin did not enhance 2-5AS levels. 2-5AS levels between sustained virological response (SVR) and non-SVR, including null responders to pegylated interferon plus ribavirin therapy were not significantly different. 2-5AS levels were significantly higher in patients treated with pegylated interferon than in those treated with non-pegylated interferon, suggesting that pegylated interferon is more potent at inducing interferon response genes resulting in an improved antiviral effect. Ribavirin did not appear to be related to interferon response gene induction.Keywords
This publication has 15 references indexed in Scilit:
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responderJournal of Medical Virology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Novel Insights into Hepatitis C Virus Replication and PersistenceAdvances in Virus Research, 2004
- Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology, 2003
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis BHepatology, 1988
- Monitoring of Interferon Therapy by Assay of (2′-5′) Oligo-Isoadenylate Synthetase in Human Peripheral White Blood CellsJournal of Interferon Research, 1981
- pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.Proceedings of the National Academy of Sciences of the United States of America, 1978